

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



友芝友生物製藥

**WUHAN YZY BIOPHARMA CO., LTD.**

**武漢友芝友生物製藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2496)**

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (“**Director(s)**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) announces that Dr. Liu Dan (“**Dr. Liu**”) has tendered his resignation as a non-executive Director due to the change in his personal work arrangement. Dr. Liu’s resignation will take effect from April 30, 2024 in accordance with the Company Law of the People’s Republic of China and other relevant laws and regulations, and the articles of association of the Company.

Dr. Liu has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Dr. Liu for his valuable contribution to the Company during his tenure of service as a non-executive Director.

By order of the Board

**Wuhan YZY Biopharma Co., Ltd.**

**Dr. Zhou Pengfei**

*Chairman of the Board, Executive Director and Chief Executive Officer*

Wuhan, PRC, April 30, 2024

*As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.*